Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics to Sequence 1,000 Genomes for NCI Pediatric Cancer Project

Premium

Complete Genomics will receive $8 million to sequence 500 tumor/normal pairs, or $8,000 per genome, as part of a National Cancer Institute initiative funded by the American Recovery and Reinvestment Act of 2009, the company said this week. The project aims to identify therapeutic targets in childhood cancers.

The contract follows on a previous phase of the project, during which the company sequenced 50 tumor/normal pairs from pediatric cancers, including acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma, osteosarcoma, and Wilms tumor.

Complete Genomics originally mentioned the NCI contract during its second-quarter earnings call Aug. 4 (CSN 8/9/2011).

The project is part of NCI's Therapeutically Applicable Research to Generate Effective Treatments Initiative. For this, its second phase, Complete Genomics will focus on identifying somatic mutations associated with specific tumor types, and will submit the data to the TARGET database.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.